title: Continuous glucose monitoring in children with type 1 diabetes.
abstract: OBJECTIVE
  To examine the feasibility of daily use of a continuous glucose monitor, the FreeStyle Navigator Continuous Glucose Monitoring System ("Navigator"), in children with type 1 diabetes (T1D).
  
  
  METHODS
  After a masked Navigator was used for 4 to 7 days to establish a baseline level of glycemic control, 30 insulin pump users with T1D (average age 11.2 years) were asked to use the Navigator daily for 13 weeks.
  
  
  RESULTS
  Subjects averaged 149 h/wk of Navigator use during the first 4 weeks, which decreased slightly to 134 h/wk during weeks 9 to 13 (P = .006). Mean hemoglobin A1c improved from 7.1% at baseline to 6.8% at 13 weeks (P = .02), and the percentage of glucose values between 71 and 180 mg/dL increased from 52% to 60% (P = .01). Subjects and parents reported high satisfaction with the Navigator on the Continuous Glucose Monitor Satisfaction Scale. Two subjects had severe skin reactions related to sensor mount adhesive.
  
  
  CONCLUSIONS
  This study indicates that incorporating real-time continuous glucose monitoring into the daily treatment of children with T1D is feasible. The results provide a compelling rationale for conducting a randomized trial of daily use of a continuous glucose monitor in children with T1D.
authors: Bruce
authors: B
authors: Buckingham
authors: Roy W
authors: RW
authors: Beck
authors: William V
authors: WV
authors: Tamborlane
authors: Dongyuan
authors: D
authors: Xing
authors: Craig
authors: C
authors: Kollman
authors: Rosanna
authors: R
authors: Fiallo-Scharer
authors: Nelly
authors: N
authors: Mauras
authors: Katrina J
authors: KJ
authors: Ruedy
authors: Michael
authors: M
authors: Tansey
authors: Stuart A
authors: SA
authors: Weinzimer
authors: Tim
authors: T
authors: Wysocki
mesh_terms: D000293:Adolescent; D015190:Blood Glucose Self-Monitoring / Q000009:adverse effects / Q000295:instrumentation; D002648:Child; D002675:Child, Preschool; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000628:therapy; D005240:Feasibility Studies; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007332:Insulin Infusion Systems; D008297:Male; D018670:Monitoring, Ambulatory / Q000009:adverse effects / Q000295:instrumentation; D017060:Patient Satisfaction; D010865:Pilot Projects
chemical_list: D006442:Glycated Hemoglobin